Author: admin

DelveInsight’s, “HR Positive/ HER2 Negative Breast Cancer Pipeline Insight, 2025,” report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape. It covers the HR Positive/ HER2 Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HR Positive/ HER2 Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook Report

Key Takeaways from the HR Positive/ HER2 Negative Breast Cancer Pipeline Report

• In August 2025, Puma Biotechnology, Inc. announced a Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy.
• In August 2025, Merck Sharp & Dohme LLC conducted a Phase 3 study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer.
• In August 2025, Relay Therapeutics, Inc. announced a Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
• DelveInsight’s HR Positive/ HER2 Negative Breast Cancer pipeline report depicts a robust space with 50+ active players working to develop 53+ pipeline therapies for HR Positive/ HER2 Negative Breast Cancer treatment.
• The leading HR Positive/ HER2 Negative Breast Cancer Companies such as Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche and others.
• Promising HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies such as TQB3616 capsule, Fulvestrant injection, Pembrolizumab, Sacituzumab Govitecan, VS-6766, Abemaciclib, Fulvestrant, Letrozole, Anastrozole, Exemestane and others.

Learn how leading HR Positive/ HER2 Negative Breast Cancer Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ HR Positive/ HER2 Negative Breast Cancer Clinical Trials Assessment

HR Positive/ HER2 Negative Breast Cancer Emerging Drugs Profile

• Camizestrant: AstraZeneca

Camizestrant is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations. The asset has been shown to promising anti-tumour profile when administered alone or in combination with palbociclib and thus, the company is running a Phase III trial for the same.

• Dato-DXd: Daiichi Sankyo, Inc.

Datopotamab deruxtecan (Dato-DXd) is an investigational currently in Phase III for HR-positive, HER2- negative breast cancer. It is a TROP2 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of the three lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.

• CX-2009: CytomX Therapeutics

CX-2009 is a Probody drug conjugate that consists of a humanized anti-CD166 monoclonal antibody conjugated to DM4, a potent microtubule inhibitor known to be active against multiple cancer types. It is currently being tested in Phase II trial in Advanced HR-Positive/HER2-Negative Breast Cancer and of Praluzatamab Ravtansine as Monotherapy and in Combination with Pacmilimab (CX-072) in Advanced Triple-Negative Breast Cancer.

• RGT-419B: Regor Therapeutics

RGT-419B is a new generation of CDK inhibitor with an optimized kinase activity spectrum. The clinical development program of RGT-419B is designed to address the unmet medical needs of patients who are refractory or have relapsed after previous treatment, providing new opportunities to improve survival and quality of life for patients with advanced/metastatic breast cancer. It is currently being tested in Phase I trial in in subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer.

The HR Positive/ HER2 Negative Breast Cancer Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of HR Positive/ HER2 Negative Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HR Positive/ HER2 Negative Breast Cancer Treatment.
• HR Positive/ HER2 Negative Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HR Positive/ HER2 Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HR Positive/ HER2 Negative Breast Cancer market.

From early-stage research to late-phase HR Positive/ HER2 Negative Breast Cancer Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ HR Positive/ HER2 Negative Breast Cancer Treatment Drugs

HR Positive/ HER2 Negative Breast Cancer Companies

Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche and others.

HR Positive/ HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

HR Positive/ HER2 Negative Breast Cancer Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Stay updated with the latest HR Positive/ HER2 Negative Breast Cancer Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ HR Positive/ HER2 Negative Breast Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the HR Positive/ HER2 Negative Breast Cancer Pipeline Report

• Coverage- Global
• HR Positive/ HER2 Negative Breast Cancer Companies- Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche and others.
• HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies- TQB3616 capsule, Fulvestrant injection, Pembrolizumab, Sacituzumab Govitecan, VS-6766, Abemaciclib, Fulvestrant, Letrozole, Anastrozole, Exemestane and others.
• HR Positive/ HER2 Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HR Positive/ HER2 Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest HR Positive/ HER2 Negative Breast Cancer Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ HR Positive/ HER2 Negative Breast Cancer Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. HR Positive/ HER2 Negative Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HR Positive/ HER2 Negative Breast Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Dato-DXd: Daiichi Sankyo, Inc.
9. Mid Stage Products (Phase II)
10. CX-2009: CytomX Therapeutics
11. Early Stage Products (Phase I)
12. RGT-419B: Regor Therapeutics
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. HR Positive/ HER2 Negative Breast Cancer- Unmet Needs
17. HR Positive/ HER2 Negative Breast Cancer- Market Drivers and Barriers
18. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “RIPK1 inhibitor Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in RIPK1 inhibitor pipeline landscape. It covers the RIPK1 Inhibitor pipeline RIPK1 inhibitor drug profiles, including RIPK1 inhibitor clinical and nonclinical stage products. It also covers the RIPK1 inhibitor therapeutics assessment by product type, stage, RIPK1 inhibitor route of administration, and RIPK1 inhibitor molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ RIPK1 Inhibitor Pipeline Outlook Report

Key Takeaways from the RIPK1 Inhibitor Pipeline Report

• DelveInsight’s RIPK1 Inhibitor pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for RIPK1 Inhibitor treatment.
• The leading RIPK1 Inhibitor Companies such as Sanofi, Sironax, Genfleet Therapeutics, Rigel Pharmaceuticals, GlaxoSmithKline, AbbVie, Sanofi, Rigel Pharmaceuticals, Voronoi, Boston Pharmaceuticals, Sironax, Sironax, Nuevolution and others.
• Promising RIPK1 Inhibitor Pipeline Therapies such as SAR443122, GFH312, R552, and others.

Learn how leading RIPK1 Inhibitor Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ RIPK1 Inhibitor Clinical Trials Assessment

RIPK1 Inhibitor Emerging Drugs Profile

• SAR443122: Sanofi

SAR443122 (DNL758) is a small molecule inhibitor of a protein known as RIPK1 (receptor-interacting serine/threonine-protein kinase 1), which is involved in the tumor necrosis factor (TNF) receptor pathway that is implicated in inflammation, immunity, and cell death. RIPK1, receptor-interacting serine/threonine-protein kinase 1, is a critical signaling protein in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body. Sanofi has successfully completed the Phase I study with peripherally-restricted RIPK1 inhibitor DNL758(c) to treat SARS-CoV-2 viral infection and conducting Phase II clinical trial to treat Cutaneous Lupus Erythematosus. Furthermore, Sanofi plans to initiate a Phase II trial of SAR443122 in patients with ulcerative colitis

• GFH312: GenFleet Therapeutics

GFH312 is a small molecule inhibitor of receptor-interacting serine/threonine protein-1(RIP1) kinase, a key regulator of the TNF-α downstream. GenFleet is the first Chinese company that moves RIPK1 inhibitor development into clinical stage. Preclinical data of GFH312 have demonstrated its effects in suppressing inflammation (peripheral and neuronal), reducing pathological as well as behavioral deficits, and improving survival in animal models with acute systemic inflammation resulting from multiple tissue injury. GFH312 effectively inhibit the activity of RIPK1, and the Phase I trial will explore its safe dose range and tolerability in healthy subjects providing basis for further clinical development.

• R552: Rigel Pharmaceuticals

R552, the drug is supposed to block an enzyme that plays a role in a wide range of cellular processes, including inflammation and cell death. Eli Lilly and Rigel Pharmaceuticals have collaborated to co-develop and commercialize Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 or RIPK1 inhibitor, for the potential treatment of immunological and neurodegenerative diseases. Rigel’s lead RIPK1 inhibitor, R552, has completed Phase I clinical trials and the planning to begin Phase II clinical trials is underway as part of the collaboration.

The RIPK1 Inhibitor Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of RIPK1 Inhibitor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for RIPK1 Inhibitor Treatment.
• RIPK1 Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• RIPK1 Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the RIPK1 Inhibitor market.

From early-stage research to late-phase RIPK1 Inhibitor Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ RIPK1 Inhibitor Treatment Drugs

RIPK1 Inhibitor Companies

Sanofi, Sironax, Genfleet Therapeutics, Rigel Pharmaceuticals, GlaxoSmithKline, AbbVie, Sanofi, Rigel Pharmaceuticals, Voronoi, Boston Pharmaceuticals, Sironax, Sironax, Nuevolution and others.

RIPK1 inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

RIPK1 Inhibitor Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Stay updated with the latest RIPK1 Inhibitor Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ RIPK1 Inhibitor Market Drivers and Barriers, and Future Perspectives

Scope of the RIPK1 Inhibitor Pipeline Report

• Coverage- Global
• RIPK1 Inhibitor Companies- Sanofi, Sironax, Genfleet Therapeutics, Rigel Pharmaceuticals, GlaxoSmithKline, AbbVie, Sanofi, Rigel Pharmaceuticals, Voronoi, Boston Pharmaceuticals, Sironax, Sironax, Nuevolution and others.
• RIPK1 Inhibitor Pipeline Therapies- SAR443122, GFH312, R552, and others.
• RIPK1 Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• RIPK1 Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest RIPK1 Inhibitor Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ RIPK1 Inhibitor Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. RIPK1 inhibitors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Mid Stage Products (Phase II)
7. SAR443122: Sanofi
8. Early Stage Products (Phase I)
9. GFH312: GenFleet Therapeutics
10. Preclinical Stage Products
11. BOS-421: Boston Pharmaceuticals
12. Inactive Products
13. RIPK1 inhibitors Key Companies
14. RIPK1 inhibitors Key Products
15. RIPK1 inhibitors- Unmet Needs
16. RIPK1 inhibitors- Market Drivers and Barriers
17. RIPK1 inhibitors- Future Perspectives and Conclusion
18. RIPK1 inhibitors Analyst Views
19. RIPK1 inhibitors Key Companies
20. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/ripk1-inhibitor-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: RIPK1 Inhibitor Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s “Multiple Myeloma Pipeline Insights 2025” report provides comprehensive insights about 75+ Multiple Myeloma Companies and 80+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Myeloma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Multiple Myeloma Treatment Landscape. Click here to read more @ Multiple Myeloma Pipeline Outlook

Key Takeaways from the Multiple Myeloma Pipeline Report

• In August 2025, Gracell Biotechnologies (Shanghai) Co., Ltd. announced a study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
• In August 2025, AbbVie conducted a study is to assess the safety and change in disease activity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in disease activity will be assessed.
• In August 2025, Pfizer announced a study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).
• DelveInsight’s Multiple Myeloma pipeline report depicts a robust space with 75+ Multiple Myeloma companies working to develop 80+ pipeline therapies for Multiple Myeloma treatment.
• The leading Multiple Myeloma Companies such as CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
• Promising Multiple Myeloma Pipeline Therapies such as TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.

Discover groundbreaking developments in Multiple Myeloma therapies! Gain in-depth knowledge of key Multiple Myeloma clinical trials, emerging drugs, and market opportunities @ Multiple Myeloma Clinical Trials Assessment

Multiple myeloma Emerging Drugs Profile

• Zevorcabtagene Autoleucel: Carsgen Therapeutics

Zevorcabtagene Autoleucel (Zevor-cel, R&D code: CT053) is an autologous fully human CAR T-cell product candidate against B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma (R/R MM). In October 2022, China National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) and has granted the priority review for zevor-cel. Zevor-cel is expected to be approved by the NMPA for the treatment of R/R MM at the end of 2023 or the beginning of 2024. In January 2023, CARsgen and Huadong Medicine entered into a collaboration agreement for the commercialization of CARsgen’s lead drug candidate, zevor-cel, in mainland China. Since reaching the agreement, teams from CARsgen and Huadong Medicine have been working together closely to implement this collaboration and prepare for the approval and commercialization of zevor-cel in China.

• Descartes 08: Cartesian Therapeutics

Descartes-08 is an autologous BCMA-targeting RNA-modified CAR T-cell therapy. Descartes-08 is engineered by mRNA transfection to express anti-BCMA CAR for a defined length of time. Descartes-08 express anti-BCMA CAR for 1 week, limiting risk of uncontrolled proliferation; produce inflammatory cytokines in response to myeloma target cells; and are highly cytolytic against myeloma cells regardless of presence of myeloma-protecting bone marrow stromal cells, exogenous a proliferation-inducing ligand, or drug resistance including IMiDs. The magnitude of cytolysis correlates with anti-BCMA CAR expression duration, indicating a temporal limit in activity. In early-stage clinical studies, Descartes-08 has been safe and well-tolerated in patients with MG and multiple myeloma. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple Myeloma.

• GC012F: Gracell Biotechnology Shanghai Co., Ltd.

GC012F is Gracell’s FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell therapy, which aims to transform cancer and autoimmune disease treatment by driving fast, deep and durable responses with improved safety profile. GC012F is currently being evaluated in clinical studies in multiple hematological cancers as well as autoimmune diseases, and has demonstrated a consistently strong efficacy and safety profile. Gracell has initiated a Phase 1b/2 trial evaluating GC012F for the treatment of relapsed/refractory multiple myeloma in the United States and a Phase 1/2 clinical trial in China is to be commenced imminently.

• CID-103: CASI Pharmaceuticals

CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody that recognizes a unique epitope on CD38. It was engineered to have strong activity against CD38 malignant cells and to reduce certain safety issues observed with existing treatments. Preclinical data of CID-103 demonstrates enhanced activity against a broad array of malignancies which express CD38 and demonstrates a better preclinical safety profile when compared to other CD38 mAbs. These attributes offer the potential for accelerated development and regulatory review, including rapid advancement into earlier lines of therapy. Currently, the drug is in the Phase I stage of its development for the treatment of Multiple Myeloma.

• STI-1492: Sorrento Therapeutics

STI-1492 is a therapeutic candidate developed by Sorrento Therapeutics for the treatment of relapsed or refractory multiple myeloma. It is an allogeneic, off-the-shelf therapy that involves the administration of Anti-CD38 A2 Dimeric Antigen Receptor T (DAR-T) cells through a single intravenous infusion. The therapy is currently being evaluated in a phase 1b, open-label, dose-escalation study involving subjects with relapsed or refractory multiple myeloma. CD38 is a transmembrane glycoprotein present on various immune cells and hematologic malignancies, and its expression has been associated with poor prognosis. Currently, the drug is in the Phase I stage of its development for the treatment of Multiple Myeloma.

The Multiple Myeloma Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Myeloma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Myeloma Treatment.
• Multiple Myeloma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Myeloma market

Stay informed about the Multiple Myeloma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Multiple Myeloma Unmet Needs

Multiple Myeloma Companies

CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix and others.

Multiple myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Multiple Myeloma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Transform your understanding of the Multiple Myeloma Pipeline! See the latest progress in drug development and clinical research @ Multiple Myeloma Market Drivers and Barriers, and Future Perspectives

Scope of the Multiple Myeloma Pipeline Report

• Coverage- Global
• Multiple Myeloma Companies- CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
• Multiple Myeloma Pipeline Therapies- TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.
• Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Multiple Myeloma Pipeline Analysis Today! @ Multiple Myeloma Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Multiple myeloma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Multiple myeloma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Venetoclax: AbbVie
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. PHE885: Novartis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. ONC 201: Oncoceutics
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. TNB 383B: TeneoBio
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Multiple myeloma Key Companies
21. Multiple myeloma Key Products
22. Multiple myeloma- Unmet Needs
23. Multiple myeloma- Market Drivers and Barriers
24. Multiple myeloma- Future Perspectives and Conclusion
25. Multiple myeloma Analyst Views
26. Multiple myeloma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Myeloma Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Acute Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Acute Lymphocytic Leukemia pipeline landscape. It covers the Acute Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Acute Lymphocytic Leukemia Research. Learn more about our innovative pipeline today! @ Acute Lymphocytic Leukemia Pipeline Outlook

Key Takeaways from the Acute Lymphocytic Leukemia Pipeline Report

• In August 2025, Pfizer announced a study in Chinese patients with relapsed or refractory CD22-positive B-cell ALL. The objective of the study is to confirm the efficacy, safety, and PK of inotuzumab ozogamicin in patients with relapsed or refractory B-cell ALL from mainland China.
• In August 2025, Juventas Cell Therapy Ltd. announced a study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.
• In August 2025, Janssen Research & Development, LLC conducted a study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D.
• In August 2025, Amgen organized a Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of R/R B-ALL, to determine the maximum tolerated dose (MTD), and recommended phase 2 dose(s) (RP2D) of SC administered blinatumomab.
• DelveInsight’s Acute Lymphocytic Leukemia pipeline report depicts a robust space with 125+ active players working to develop 130+ pipeline therapies for Acute Lymphocytic Leukemia treatment.
• The leading Acute Lymphocytic Leukemia Companies such as Orca Biosystems, Inc, Jazz Pharmaceuticals, Shenzhen TargetRx, Inc, Cellectis, ADC Therapeutics S.A., Kunming Hope of Health Hospital, Beam Therapeutics Inc., Shenzhen BinDeBio Ltd., Kite, A Gilead Company, Sumitomo Pharma America, Inc., In8bio Inc., Fate Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd., Janssen Research & Development, LLC, Medolution Ltd., Kymera Therapeutics, Inc., Kite, A Gilead Company | Gilead Sciences, Newave Pharmaceutical Inc, Servier, Meryx, Inc., Armaceutica, Inc., Hangzhou Qihan Biotech Co., Ltd., Nanjing Bioheng Biotech, Sanofi, Syndax Pharmaceuticals, Vincerx Pharma, Inc. and others.
• Promising Acute Lymphocytic Leukemia Pipeline Therapies such as Omitted Doxorubicin, Blinatumomab, Dexamethasone, Vincrisitne, Recombinant Asparaginase, Inotuzumab Ozogamicin and others.

Stay informed about the cutting-edge advancements in Acute Lymphocytic Leukemia treatments. Download for updates and be a part of the revolution in care @ Acute Lymphocytic Leukemia Clinical Trials Assessment

Acute Lymphocytic Leukemia Emerging Drugs Profile

• Orca-T: Orca Biosystems, Inc.

Orca-T is an investigational high-precision cell therapy designed to replace a patient’s cancerous blood and immune system with a healthy one while dramatically lowering their risk of developing GvHD and other potentially life-threatening side effects. In the Phase Ib/II study, when measured against a concurrent, nonrandomized single-center comparator for allogeneic transplant patients, Orca-T demonstrated preliminary evidence of significantly higher GvHD-free, relapse-free survival rates after 1 year, improved relapse-free survival rates and lower rates of chronic GvHD. Currently, the drug is in Phase III stage of its development for the treatment of ALL.

• TGRX-814: Shenzhen TargetRx, Inc.

TGRX-814 is a highly selective inhibitor of the BCL2 (over BCL-XL) for the treatment of CLL with or without the del(17p)/TP53 mutation, NHL, SLL, DLBL, MM, etc. Notably, TGRX-814 has an excellent selectivity profile for BCL-XL. TGRX-814 is modified and optimized through classical bioisosterism and molecule simulation technologies. In-vitro and in-vivo assays have shown that TGRX-814 improves oral metabolism, increases in vivo exposure, and reduces compound clearance while maintaining in vitro and in vivo bioactivity. Moreover, TGRX-814 obtained over 2-fold increase in bioavailability compared to the marketed drug Venetoclax, resulting in a significant increase in efficacy. Currently, the drug is in Phase I/II stage of its development for the treatment of ALL.

• UCART22: Cellectis

UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Like CD19, CD22 is a cell surface antigen expressed from the pre-B-cell stage of development through mature B-cells. CD22 expression occurs in more than 90% of patients with B-ALL. It is currently in phase I stage of development. Currently, the drug is in Phase I stage of its development for the treatment of ALL.

The Acute Lymphocytic Leukemia Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Lymphocytic Leukemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Lymphocytic Leukemia Treatment.
• Acute Lymphocytic Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Lymphocytic Leukemia market

Learn more about Acute Lymphocytic Leukemia Drugs opportunities in our groundbreaking Colo Acute Lymphocytic Leukemia Research and development projects @ Acute Lymphocytic Leukemia Unmet Needs

Acute Lymphocytic Leukemia Companies

Orca Biosystems, Inc, Jazz Pharmaceuticals, Shenzhen TargetRx, Inc, Cellectis, ADC Therapeutics S.A., Kunming Hope of Health Hospital, Beam Therapeutics Inc., Shenzhen BinDeBio Ltd., Kite, A Gilead Company, Sumitomo Pharma America, Inc., In8bio Inc., Fate Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd., Janssen Research & Development, LLC, Medolution Ltd., Kymera Therapeutics, Inc., Kite, A Gilead Company | Gilead Sciences, Newave Pharmaceutical Inc, Servier, Meryx, Inc., Armaceutica, Inc., Hangzhou Qihan Biotech Co., Ltd., Nanjing Bioheng Biotech, Sanofi, Syndax Pharmaceuticals, Vincerx Pharma, Inc. and others.

Acute Lymphocytic Leukemia (ALL) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Acute Lymphocytic Leukemia Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Acute Lymphocytic Leukemia Treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Acute Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspectives

Scope of the Acute Lymphocytic Leukemia Pipeline Report

• Coverage- Global
• Acute Lymphocytic Leukemia Companies- Orca Biosystems, Inc, Jazz Pharmaceuticals, Shenzhen TargetRx, Inc, Cellectis, ADC Therapeutics S.A., Kunming Hope of Health Hospital, Beam Therapeutics Inc., Shenzhen BinDeBio Ltd., Kite, A Gilead Company, Sumitomo Pharma America, Inc., In8bio Inc., Fate Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd., Janssen Research & Development, LLC, Medolution Ltd., Kymera Therapeutics, Inc., Kite, A Gilead Company | Gilead Sciences, Newave Pharmaceutical Inc, Servier, Meryx, Inc., Armaceutica, Inc., Hangzhou Qihan Biotech Co., Ltd., Nanjing Bioheng Biotech, Sanofi, Syndax Pharmaceuticals, Vincerx Pharma, Inc. and others.
• Acute Lymphocytic Leukemia Pipeline Therapies- Omitted Doxorubicin, Blinatumomab, Dexamethasone, Vincrisitne, Recombinant Asparaginase, Inotuzumab Ozogamicin and others.
• Acute Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acute Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Acute Lymphocytic Leukemia Pipeline on our website @ Acute Lymphocytic Leukemia Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Acute-Lymphocytic-Leukemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acute-Lymphocytic-Leukemia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Orca-T: Orca Biosystems, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Product Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. TGRX-814: Shenzhen TargetRx, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Acute-Lymphocytic-Leukemia Key Companies
21. Acute-Lymphocytic-Leukemia Key Products
22. Acute-Lymphocytic-Leukemia- Unmet Needs
23. Acute-Lymphocytic-Leukemia- Market Drivers and Barriers
24. Acute-Lymphocytic-Leukemia- Future Perspectives and Conclusion
25. Acute-Lymphocytic-Leukemia Analyst Views
26. Acute-Lymphocytic-Leukemia Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Lymphocytic Leukemia Pipeline Outlook Report 2025: Key 125+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, Non-Small-Cell Lung Cancer (NSCLC) Pipeline Insights 2025” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations that are transforming the industry. @ Non-Small Cell Lung Cancer Pipeline Outlook Report

Key Takeaways from the Non-Small Cell Lung Cancer Pipeline Report

• In August 2025, AbbVie announced a study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) inhibitor (budigalimab) to adult participants to treat NSCLC.
• In August 2025, Merck Sharp & Dohme LLC announced a study aims to determine the effectiveness of adding other treatments, including the human epidermal growth factor receptor 3-directed antibody-drug conjugate (HER3-DXd) patritumab deruxtecan, to pembrolizumab, with or without chemotherapy. The primary goals are to assess safety and efficacy of the treatments.
• In August 2025, BeiGene conducted a study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (< 50%).
• DelveInsight’s Non-Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Non-Small Cell Lung Cancer treatment.
• The leading Non-Small Cell Lung Cancer Companies such as Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience – Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech and others.
• Promising Non-small cell lung cancer pipeline therapies such as Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others.

Learn how leading Non-Small Cell Lung Cancer Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Non-Small Cell Lung Cancer Clinical Trials Assessment

Non-Small Cell Lung Cancer Emerging Drugs Profile

• V940: Merck Sharp & Dohme LLC

V940 is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient’s tumor. It is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient’s tumor. Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity. The drug is in Phase III stage for the treatment of NSCLC.

• QL1706: Qilu Pharmaceutical Co., Ltd.

QL1706 is an investigational bifunctional antibody with additional anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody could increase the anti-tumor effect of anti-programmed cell death 1 (PD-1) antibody. QL1706 is a novel dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA4 IgG1 antibodies produced by a single cell line. The drug is in Phase III stage for the treatment of NSCLC.

• Zenocutuzumab (MCLA-128): Merus N.V.

Zenocutuzumab (MCLA-128; Zeno) is a Biclonics antibody that overcomes HER3 mediated NRG1 (or NRG1 fusion) signaling in tumor cells. Zeno docks on HER2, then binds to and blocks the NRG1 fusion-HER3 interaction and HER3 heterodimerization with HER2. It has a dual mechanism against cancer, as it prevents NRG1 fusions from binding to the protein HER3 and it blocks the interaction of HER3 with HER2, which the cancer cells depend on to survive and multiply. Currently, the drug is in Phase II stage for the treatment of NSCLC.

• ZW49: Zymeworks BC Inc.

ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as ZW25 but armed with a cytotoxic payload. A biparatopic (targeting two different non-overlapping epitopes on ERBB2, on extracellular domains 2 (ECD2) and 4 (ECD4). ZW25 is an anti-HER2 biparatopic antibody which binds to the same domains as trastuzumab and pertuzumab. ZW25 simultaneously binds two distinct sites on HER2, a protein expressed on many types of cancer cells. This unique design results in multiple mechanisms of action, including dual HER2 signal blockade, increased antibody binding, receptor clustering, and removal of HER2 from the cell surface, and potent effector function. ZW49 is in Phase I of clinical trials for the treatment of non-small cell lung cancer.

The Non-Small Cell Lung Cancer Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Non-Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Small Cell Lung Cancer Treatment.
• Non-Small Cell Lung Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non-Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Small Cell Lung Cancer market.

From early-stage research to late-phase Non-Small Cell Lung Cancer Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Non-Small Cell Lung Cancer Treatment Drugs

Non-Small Cell Lung Cancer Companies

Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience – Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech and others.

Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay updated with the latest Non-Small Cell Lung Cancer Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Non-Small Cell Lung Cancer Pipeline Report

• Coverage- Global
• Non-Small Cell Lung Cancer Companies- Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience – Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech and others.
• Non-Small Cell Lung Cancer Pipeline Therapies- Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others.
• Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Non-Small Cell Lung Cancer Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Non-Small Cell Lung Cancer Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Non-Small-Cell Lung cancer (NSCLC) : Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Non-Small-Cell Lung cancer (NSCLC) – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. V940: Merck Sharp & Dohme LLC
9. Mid Stage Products (Phase II)
10. Zenocutuzumab (MCLA-128): Merus N.V.
11. Early Stage Products (Phase I)
12. ZW49: Zymeworks BC Inc.
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Non-Small-Cell Lung cancer (NSCLC) Key Companies
17. Non-Small-Cell Lung cancer (NSCLC) Key Products
18. Non-Small-Cell Lung cancer (NSCLC) – Unmet Needs
19. Non-Small-Cell Lung cancer (NSCLC) – Market Drivers and Barriers
20. Non-Small-Cell Lung cancer (NSCLC) – Future Perspectives and Conclusion
21. Non-Small-Cell Lung cancer (NSCLC) Analyst Views
22. Non-Small-Cell Lung cancer (NSCLC) Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Small Cell Lung Cancer Pipeline Outlook Report 2025: Key 100+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Epidermolysis Bullosa Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 21+ pipeline drugs in Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epidermolysis Bullosa pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Epidermolysis Bullosa Pipeline Outlook Report

Key Takeaways from the Epidermolysis Bullosa Pipeline Report

• In July 2025, Castle Creek Biosciences, LLC. announced a study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
• In July 2025, Krystal Biotech, Inc. announced a study (protocol NHS) for at least 12 weeks and that meet all other eligibility criteria receive weekly ophthalmic administration of Investigational product (IP), KB803 or placebo, for the first 12-week intervention period. During the second intervention period subjects will receive the alternative IP for an additional 12 weeks. IP will be administered in the home setting by a healthcare provider.
• DelveInsight’s Epidermolysis Bullosa pipeline report depicts a robust space with 20+ active players working to develop 21+ pipeline therapies for Epidermolysis Bullosa treatment.
• The leading Epidermolysis Bullosa Companies such as Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma and others.
• Promising Epidermolysis Bullosa Pipeline Therapies such as diacerein 1% ointment, allo-APZ2-OTS, Serlopitant Tablet, SD-101-6.0 cream, Oleogel-S10, EB-101, KB803, CX501 and others.

Learn how leading Epidermolysis Bullosa Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Epidermolysis Bullosa Clinical Trials Assessment

Epidermolysis Bullosa Emerging Drugs Profile

• EB-101: Abeona Therapeutics

EB-101 is an autologous, engineered cell therapy for RDEB, a rare connective tissue disorder without an approved treatment in which patients suffer with severe epidermal wounds that impact the length and quality of their lives. People with RDEB have a defect in the COL7A1 gene, leaving them unable to produce Type VII collagen that helps anchor the dermal and epidermal layers of the skin. In November 2024, Abeona Therapeutics’ biologics license application (BLA) for prademagene zamikeracel (pz-cel; EB-101), an investigational autologous gene-corrected epidermal sheet therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB), has been accepted for filing by the FDA. The agency has set the Prescription Drug User Fee Act (PDUFA) action date for the BLA for April 29, 2025.

• INM-755: InMed Pharmaceuticals

INM-755 is a cannabinol (CBN) cream intended as a topical therapy to treat symptoms associated with epidermolysis bullosa (EB) and potentially other dermatological diseases. Preclinical data demonstrate that INM-755 (cannabinol) cream may help relieve hallmark EB symptoms, such as pain, inflammation, wound healing and itch, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Epidermolysis Bullosa.

• BM-3103: BioMendics

The company’s lead product in development, BM-3103, is a patented topical gel. It is currently being studied in a Phase I/IIa trial for epidermolysis bullosa simplex, with additional indications in the pipeline. MTORX technology is an investigational platform encompassing therapeutic candidate, BM-3103.

The Epidermolysis Bullosa Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Epidermolysis Bullosa with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epidermolysis Bullosa Treatment.
• Epidermolysis Bullosa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epidermolysis Bullosa market.

From early-stage research to late-phase Epidermolysis Bullosa Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Epidermolysis Bullosa Treatment Drugs

Epidermolysis Bullosa Companies

Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma and others.

Epidermolysis bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Epidermolysis Bullosa Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Stay updated with the latest Epidermolysis Bullosa Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Epidermolysis Bullosa Market Drivers and Barriers, and Future Perspectives

Scope of the Epidermolysis Bullosa Pipeline Report

• Coverage- Global
• Epidermolysis Bullosa Companies- Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma and others.
• Epidermolysis Bullosa Pipeline Therapies- diacerein 1% ointment, allo-APZ2-OTS, Serlopitant Tablet, SD-101-6.0 cream, Oleogel-S10, EB-101, KB803, CX501 and others.
• Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Epidermolysis Bullosa Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Epidermolysis Bullosa Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Epidermolysis bullosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. EB-101: Abeona Therapeutics
8. Mid Stage Products (Phase II)
9. INM-755: InMed Pharmaceuticals
10. Early Stage Products (Phase I)
11. Drug name: Company name
12. Preclinical and Discovery Stage Products
13. Drug name: Company name
14. Inactive Products
15. Epidermolysis bullosa Key Companies
16. Epidermolysis bullosa Key Products
17. Epidermolysis bullosa- Unmet Needs
18. Epidermolysis bullosa- Market Drivers and Barriers
19. Epidermolysis bullosa- Future Perspectives and Conclusion
20. Epidermolysis bullosa Analyst Views
21. Epidermolysis bullosa Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epidermolysis Bullosa Pipeline Outlook Report 2025: Key 20+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Cough in Idiopathic Pulmonary Fibrosis (IPF) Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cough in Idiopathic Pulmonary Fibrosis (IPF) pipeline landscape. It covers the Cough in Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cough in Idiopathic Pulmonary Fibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Cough in Idiopathic Pulmonary Fibrosis Pipeline Outlook Report

Key Takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report

• In August 2025, Boehringer Ingelheim announced a study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF. Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part.
• DelveInsight’s Cough in Idiopathic Pulmonary Fibrosis pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Cough in Idiopathic Pulmonary Fibrosis treatment.
• The leading Cough in Idiopathic Pulmonary Fibrosis Companies such as Trevi Therapeutics, Algernon Pharmaceuticals, Melius Pharma and others.
• Promising Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapies such as Orvepitant Maleate, Gefapixant, BI 1839100, PA101, ME-015 (Suplatast Tosilate) and others.

Learn how leading Cough in Idiopathic Pulmonary Fibrosis Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Cough in Idiopathic Pulmonary Fibrosis Clinical Trials Assessment

Cough in Idiopathic Pulmonary Fibrosis Emerging Drugs Profile

• Haduvio (nalbuphine ER): Trevi Therapeutics

Haduvio (nalbuphine ER) has a novel approach to chronic cough by working on two important receptors that are critical mediators of cough, in both the central and peripheral nerves. Haduvio has a dual mechanism of action, acting as both an agonist (activator) to the kappa opioid receptor and as an antagonist (blocker) to the body’s mu opioid receptor. By targeting these receptors along the complete cough pathway, it has the potential to work regardless of whether the initial cough trigger originates in the lung or in the central nervous system. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF).

The Cough in Idiopathic Pulmonary Fibrosis Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Cough in Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cough in Idiopathic Pulmonary Fibrosis Treatment.
• Cough in Idiopathic Pulmonary Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cough in Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cough in Idiopathic Pulmonary Fibrosis market.

From early-stage research to late-phase Cough in Idiopathic Pulmonary Fibrosis Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Cough in Idiopathic Pulmonary Fibrosis Treatment Drugs

Cough in Idiopathic Pulmonary Fibrosis Companies

Trevi Therapeutics, Algernon Pharmaceuticals, Melius Pharma and others.

Cough in Idiopathic Pulmonary Fibrosis (IPF) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Cough in Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay updated with the latest Cough in Idiopathic Pulmonary Fibrosis Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Cough in Idiopathic Pulmonary Fibrosis Market Drivers and Barriers, and Future Perspectives

Scope of the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report

• Coverage– Global
• Cough in Idiopathic Pulmonary Fibrosis Companies- Trevi Therapeutics, Algernon Pharmaceuticals, Melius Pharma and others.
• Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapies- Orvepitant Maleate, Gefapixant, BI 1839100, PA101, ME-015 (Suplatast Tosilate) and others.
• Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Cough in Idiopathic Pulmonary Fibrosis Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Cough in Idiopathic Pulmonary Fibrosis (IPF): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cough in Idiopathic Pulmonary Fibrosis (IPF)– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Mid Stage Products (Phase II)
10. Haduvio (nalbuphine ER): Trevi Therapeutics
11. Early Stage Products (Phase I)
12. Drug name: Company name
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Cough in Idiopathic Pulmonary Fibrosis (IPF) Key Companies
17. Cough in Idiopathic Pulmonary Fibrosis (IPF) Key Products
18. Cough in Idiopathic Pulmonary Fibrosis (IPF)- Unmet Needs
19. Cough in Idiopathic Pulmonary Fibrosis (IPF)- Market Drivers and Barriers
20. Cough in Idiopathic Pulmonary Fibrosis (IPF)- Future Perspectives and Conclusion
21. Cough in Idiopathic Pulmonary Fibrosis (IPF) Analyst Views
22. Cough in Idiopathic Pulmonary Fibrosis (IPF) Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cough in Idiopathic Pulmonary Fibrosis Pipeline Outlook Report 2025: Key 5+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Vascular Dementia Pipeline Insight, 2025,” report provides comprehensive insights about 11+ companies and 11+ pipeline drugs in Vascular Dementia pipeline landscape. It covers the Vascular Dementia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Vascular Dementia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Vascular Dementia Pipeline Outlook Report

Key Takeaways from the Vascular Dementia Pipeline Report

• In February 2025, Ever Neuro Pharma GmbH conducted a clinical trial of the global risk-benefit assessment of Cerebrolysin as compared to Placebo in patients with genetically proven CADASIL. In addition, a traditional approach will be taken based on an evaluation of the separate risk and benefit domains in comparison with placebo.
• DelveInsight’s Vascular Dementia pipeline report depicts a robust space with 11+ active players working to develop 11+ pipeline therapies for Vascular Dementia treatment.
• The leading Vascular Dementia Companies such as Merz Pharma, CSPC Ouyi Pharmaceutical, Resverlogix Corporation, Autifony Therapeutics, Beijing Joekai Biotechnology, Neuraltus Pharmaceuticals and others.
• Promising Vascular Dementia Pipeline Therapies such as Butylphthalide soft capsule, Galantamine, Fufangdanshen Tablets, donepezil hydrochloride (Aricept), Rivastigmine, Prospekta, Cerebrolysin and others.

Learn how leading Vascular Dementia Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Vascular Dementia Clinical Trials Assessment

Vascular Dementia Emerging Drugs Profile

• Butylphthalide: CSPC Ouyi Pharmaceutical

Butylphthalide (NBP) is a compound found in Chinese celery seed extracts that can improve cognitive functions and may decrease Amyloid-beta levels in Alzheimer′s disease. NBP has antioxidant activities and may protect against oxidative/nitrosative stress, mitochondrial impairment and apoptosis. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Vascular Dementia.

The Vascular Dementia Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Vascular Dementia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vascular Dementia Treatment.
• Vascular Dementia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Vascular Dementia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vascular Dementia market.

From early-stage research to late-phase Vascular Dementia Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Vascular Dementia Treatment Drugs

Vascular Dementia Companies

Merz Pharma, CSPC Ouyi Pharmaceutical, Resverlogix Corporation, Autifony Therapeutics, Beijing Joekai Biotechnology, Neuraltus Pharmaceuticals and others.

Vascular Dementia Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Vascular Dementia Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Stay updated with the latest Vascular Dementia Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Vascular Dementia Market Drivers and Barriers, and Future Perspectives

Scope of the Vascular Dementia Pipeline Report

• Coverage- Global
• Vascular Dementia Companies- Merz Pharma, CSPC Ouyi Pharmaceutical, Resverlogix Corporation, Autifony Therapeutics, Beijing Joekai Biotechnology, Neuraltus Pharmaceuticals and others.
• Vascular Dementia Pipeline Therapies- Butylphthalide soft capsule, Galantamine, Fufangdanshen Tablets, donepezil hydrochloride (Aricept), Rivastigmine, Prospekta, Cerebrolysin and others.
• Vascular Dementia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Vascular Dementia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Vascular Dementia Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Vascular Dementia Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Vascular Dementia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Vascular Dementia – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Vascular Dementia Collaboration Deals
9. Late Stage Products (Phase III)
10. Butylphthalide: CSPC Ouyi Pharmaceutical
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Early stage products (Phase I)
14. Drug name: Company name
15. Inactive Products
16. Vascular Dementia Key Companies
17. Vascular Dementia Key Products
18. Vascular Dementia- Unmet Needs
19. Vascular Dementia- Market Drivers and Barriers
20. Vascular Dementia- Future Perspectives and Conclusion
21. Vascular Dementia Analyst Views
22. Vascular Dementia Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/vascular-dementia-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vascular Dementia Pipeline Outlook Report 2025: Key 11+ Companies and Breakthrough Therapies Shaping the Future Landscape